Not applicableUnknownNCT03671538What this trial is testingNon Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and CisplatinWho this might be right forNon-squamous Non-small Cell Lung Cancer Lingyu Luo 62
Testing effectiveness (Phase 2)Study completedNCT02409368What this trial is testingAn Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCWho this might be right forNon-Small Cell Lung Cancer Bristol-Myers Squibb 812
Early research (Phase 1)Study completedNCT03652077What this trial is testingA Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesWho this might be right forCervical CancerGastric CancerStomach Cancer+18 more Incyte Corporation 40
Large-scale testing (Phase 3)Ended earlyNCT01244191What this trial is testingTivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerWho this might be right forNon Squamous, Non-small-cell Lung Cancer Daiichi Sankyo 1,048
Early research (Phase 1)Looking for participantsNCT07503808What this trial is testingIDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesWho this might be right forEsophageal Squamous Cell CarcinomaHigh Grade Serous Ovarian CancerHead and Neck Squamous Cell Carcinoma+5 more IDEAYA Biosciences 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06142617What this trial is testingA Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.Who this might be right forNon Small Cell Lung CancerImmune Checkpoint InhibitorEGFR Exon 21 Mutation Peking Union Medical College Hospital 37
Large-scale testing (Phase 3)UnknownNCT02332512What this trial is testingStudy of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Who this might be right forCarcinoma, Non-Small-Cell Lung Jiangsu HengRui Medicine Co., Ltd. 417
Early research (Phase 1)Ended earlyNCT06546553What this trial is testingLearn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.Who this might be right forNeoplasmsNon-small-cell Lung CancerSquamous Cell Carcinoma of the Head and Neck+3 more Pfizer 10
Early research (Phase 1)Active Not RecruitingNCT06147037What this trial is testingA Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursWho this might be right forAdvanced Solid TumorMetastatic Colorectal CarcinomaHead and Neck Squamous Cell Carcinoma+4 more AstraZeneca 13
Testing effectiveness (Phase 2)WithdrawnNCT00951444What this trial is testingGemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerWho this might be right forLung Cancer Alliance for Clinical Trials in Oncology
Early research (Phase 1)UnknownNCT05311618What this trial is testingStudy of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsWho this might be right forPancreatic CancerBreast CancerGastric Cancer+13 more NGM Biopharmaceuticals, Inc 71
Testing effectiveness (Phase 2)Study completedNCT01138163What this trial is testingStudy of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung CancerWho this might be right forNon-small-cell Lung Cancer Peregrine Pharmaceuticals 121
Testing effectiveness (Phase 2)UnknownNCT04846452What this trial is testingSintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLCWho this might be right forMetastatic NSCLCRecurrent NSCLCAdvanced Non-Small Cell Squamous Lung Cancer The First Affiliated Hospital with Nanjing Medical University 40
Early research (Phase 1)Ended earlyNCT06870487What this trial is testingLearn About the Study Medicine Called PF-08046032 in People With Advanced CancersWho this might be right forPeripheral T Cell LymphomaDiffuse Large B-cell LymphomaClassical Hodgkin Lymphoma+3 more Pfizer 6
Early research (Phase 1)Ended earlyNCT05983133What this trial is testingPF-08046052/SGN-EGFRd2 in Advanced Solid TumorsWho this might be right forColorectal NeoplasmsCarcinoma, Non-Small-Cell LungSquamous Cell Carcinoma of the Head and Neck+1 more Seagen, a wholly owned subsidiary of Pfizer 68
Early research (Phase 1)Ended earlyNCT06158958What this trial is testingAssess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsWho this might be right forSolid Tumors AbbVie 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05403385What this trial is testingStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung CancerWho this might be right forMetastatic NSCLC - Non-Small Cell Lung CancerLocally Advanced NSCLC - Non-Small Cell Lung Cancer iTeos Therapeutics 36
Testing effectiveness (Phase 2)Looking for participantsNCT07360743What this trial is testingImmunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsWho this might be right forNon Small Cell Lung Cancer (Squamous or Non Squamous) UNICANCER 275
Testing effectiveness (Phase 2)Active Not RecruitingNCT00334815What this trial is testingCombination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryWho this might be right forLung AdenocarcinomaLung Adenosquamous CarcinomaLung Large Cell Carcinoma+4 more National Cancer Institute (NCI) 29
Large-scale testing (Phase 3)Looking for participantsNCT06692738What this trial is testingA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer AstraZeneca 1,160